To ensure that a commercial biomanufacturing process is in a state of control, life science companies must create and successfully execute initiatives to meet continued process verification (CPV) and other monitoring guidelines.
Biopharmaâs Resilience to Future Pandemics Relies on Manufacturing Innovation
Source: 4X-image/Getty Images
Manufacturing innovation and collaboration with technology developers will be vital to maintaining the supply of medicines in future public health emergencies, according to the organizations behind a new study. The researchâcalled the Global Biopharma Resilience Indexâwas carried out by Cytiva and consulting firm Longitude. The aim was to rank biopharma capabilities and resilience in 20 countries, scoring each on five factors critical to meeting demand during a public health crisis.
The study also revealed some major shortcoming chains, says Cytiva chief innovation officer, Dirk Voelkel, PhD.